Precision Health and PGx Podcast

Significant challenges to widescale clinical implementation of PGx include a lack of physician experience using PGx test data or confidence in interpreting PGx test data and integrating the data into the medication therapy management process. For PGx to be most impactful, prescribers must consider PGx data within the context of other non-genetic patient-specific factors. Pharmacists may help prescribers with PGx test data by creating a summary of medication therapy management recommendations for the patient that streamlines PGx report flags and identifies other pharmacotherapy interventions the pharmacist recognizes while applying non-genetic patient-specific data to the PGx test data. In this episode of the PGx for Pharmacists podcast, Dr. Becky Winslow discusses the research study, "Pharmacist Consult Reports to Support Pharmacogenomics Report Interpretation," with two of the research investigators, Dr. Anna Langerveld and Dr. David Bright. Dr. Langerveld and Dr. Bright share how this research adds to the growing evidence that clinical pharmacists can help improve the utility of PGx and prescribing. They also share how their study described a process for reducing PGx laboratory report information to a single page of patient-specific clinical recommendations. Lastly, they share that while clinical decision support tools are becoming more routine for pharmacogenomic management, the pharmacists in this study reduced the number of report-based alerts independent of sophisticated clinical decision support informatics. Anna Langerveld, Ph.D., is the Founder and President of Genemarkers, a contract research organization and CLIA/CAP certified testing laboratory specializing in genomics. Anna received her B.A. in Psychology from SUNY Binghamton and her Ph.D. from the Interdisciplinary Program in Neurosciences at Tulane University. After receiving her Ph.D., Anna served as a Research Assistant Professor at Western Michigan University. She founded Genemarkers in 2008. Under her leadership, Michigan Celebrates Small Business recognized the Company as one of the Top 50 Michigan Companies to watch. Anna is an author of peer-reviewed publications, an NIH grant recipient, and an invited speaker at a wide range of national meetings. Anna currently serves as an adjunct professor and an advisory board member for the Manchester University pharmacogenomics program and holds a community faculty position at the Western Michigan University Homer Stryker M.D. School of Medicine. Anna has been instrumental in developing strategic community partnerships to implement the use of genomics in clinical care, with a particular focus on mental health and underserved populations. Dr. David Bright is a Professor of Pharmacy at Ferris State University, where he has taught therapeutics and medication therapy management. He received his PharmD degree from the University of Toledo, completed a community pharmacy residency with Kroger Pharmacy and the University of Toledo, and served on the faculty at the Ohio Northern University as a community pharmacy residency program director. His research has primarily involved the pragmatic implementation and improvement of non-dispensing pharmacy services, particularly in the outpatient setting. Most recently, that has involved the integration of pharmacogenomics into clinical practice through community pharmacy and ambulatory care practice models. Research discussed in the podcast episode: Bright D, Saadeh C, DeVuyst-Miller S, Sohn M, Choker A, Langerveld A. Pharmacist Consult Reports to Support Pharmacogenomics Report Interpretation. Pharmgenomics Pers Med. 2020 Dec 10;13:719-724. doi: 10.2147/PGPM.S276687. PMID: 33328756; PMCID: PMC7735940. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7735940/ Learn more about your ad choices. Visit megaphone.fm/adchoices

PART TWO: Pharmacogenomics Education is critical to advancing the Pharmacist's optimal impact on medication management as a tool to ensure the drugs prescribed work as intended. The State of the Industry -- Pharmacogenomics Education Clinical pharmacogenomics activities may include designing patient-specific drug and dosage regimens based on genetic profile, documenting clinical recommendations, educating pharmacists and other health care professionals, and recommending testing Advanced training in pharmacogenomics may open up more practice opportunities for pharmacists, such as developing clinical decision support tools in electronic health record systems that guide prescribers on appropriate drug therapy regimens based on genetic profiles. Additionally, pharmacists can develop institutional guidelines and processes for implementing clinical pharmacogenomics services into various practice settings. Pharmacists can also develop patient education materials to explain the significance of the tests and serve as expert consultants in a pharmacogenomics service. Special guest: David Hurley PhD. David Hurley grew up in Dunwoody, GA, then earned a BS in Biology and Physics from Guilford College in Greensboro, NC, in 1979. He received his PhD in Molecular and Cellular Biology from Penn State University in 1986. He joined the faculty in Cell and Molecular Biology at Tulane University in New Orleans in 1992. He developed "Cellular Biochemistry" as a senior-level course for premedical students, while maintaining a research focus on the regulation of gene transcription of the Growth Hormone gene in the pituitary. Dr Hurley was an National Science Foundation CAREER program awardee from 1996-2004, and was co-investigator on a National Institutes of Health grant for 17 years. After the devastation of Hurricane Katrina, he joined the Gatton School of Pharmacy at East Tennessee State University as an inaugural faculty member in July, 2007, as Professor and Vice-Chair in the Department of Pharmaceutical Sciences. He has 45 publications, is a member of The Endocrine Society, the Society for Neuroscience, the AACP, and has been a grant reviewer for 6 years with the National Institute for Diabetes, Digestive and Kidney Diseases. Our host: Becky Winslow, PharmD Dr. Becky Winslow is a co-host on PGX for Pharmacists. She’s an accomplished Doctor of Clinical Pharmacy with more than twenty years of clinical pharmacotherapy and pharmacy business operations experience, which includes seven years of direct patient facing care, seven years of pharmacy management experience and six years of experience as a medical science liaison in the pharmacogenomics field. Becky Winslow excels at developing and managing collaborative relationships with healthcare professionals and key opinion leaders to stay abreast of emerging trends and to achieve project goals. Becky Winslow is an articulate communicator with extensive background in gathering and critically analyzing research and data; translating complex content into a level appropriate to the target audience; writing clinical and marketing content; presenting; teaching; and training. This episode of the PGX for Pharmacist's podcast is brought to you by RxSafe. Thanks RxSafe for Sponsoring this episode: RxSafe.com See omnystudio.com/listener for privacy information. Learn more about your ad choices. Visit megaphone.fm/adchoices

Thanks for joining us today as our host, Dr. Jamie Wilkey talks with a patient, Kristen, who strongly feels that PGx testing saved her life. Join us for a patient’s side of the story today! You may reach Kristen at her website: https://www.imnotcrazyproject.org/ her Facebook page: https://www.facebook.com/imnotcrazyproject or on LinkedIn: https://www.linkedin.com/in/kristen-ruth-davis-5540142a/ You may reach Jamie at her website: drjamiewilkey.com or on her LinkedIn page: https://www.linkedin.com/in/dr-jamie-wilkey/ *This episode discusses mental health and suicidal ideation. While it is not discussed in great detail, if you are having thoughts of ending your own life we strongly encourage you to push pause and call the National Suicide Prevention Hotline right away at 800-273-8255* References: IQVIA Institute for Human Data Science. Medicine Use and Spending in the U.S. https://www.iqvia.com/insights/the-iqvia-institute/reports/medicine-use-and-spending-in-the-us-a-review-of-2018-and-outlook-to-2023 Published May 2019. Accessed June 10, 2020. Spear BB, Heath-Chiozzi M, Hu J. Clinical application of pharmacogenetics. Trends Mol. Med. 2001; 7, 201–204. Table of Pharmacogenomic Biomarkers in Drug Labeling. U.S. Food and Drug Administration website.: https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labelinghttps://www.fda.gov/Drugs/ScienceResearch/ucm572698.htm Accessed June 10, 2020. Preventable Adverse Drug Reactions: A Focus on Drug Interactions. U.S. Food and Drug Administration website. www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm110632.htm. Accessed June 10, 2020. Van Driest SL, Shi Y, Bowton EA, et al. Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing. Clin Pharmacol Ther. 2014; 95(4):423‐431. Learn more about your ad choices. Visit megaphone.fm/adchoices